Clinical Research Directory

Inclusion Criteria: * Age 18-75; * Meet the diagnostic criteria for community-acquired pneumonia or hospital-acquired pneumonia; * The etiological results of sputum or alveolar lavage fluid suggested MDR-KP infection; * The patient or his family members voluntarily participated, collected alveolar lavage fluid and stool samples, agreed to perform FMT treatment, and signed the informed consent. Exclusion Criteria: * Subjects with persistent bronchial asthma, severe pulmonary dysfunction, or inability to tolerate bronchoscopy; * Patients with severe damage of intestinal barrier such as sepsis and digestive tract perforation due to various reasons; * Those currently diagnosed with explosive colitis or toxic megacolon have gastroesophageal reflux disease or peptic ulcer; Subjects taking probiotics within 6 months; * Enteral nutrition patients who could not tolerate 50% of heat calorie requirements due to severe diarrhea, significant fibrous intestinal stenosis, severe gastrointestinal bleeding, high-flow intestinal fistula and other reasons. * Patients with obvious bleeding tendency, severe pulmonary hypertension, superior vena cava obstruction, and aortic aneurysm rupture risk; * Patients with malignant hypertension, recent myocardial infarction (≤6 months), severe arrhythmia, and cardiac insufficiency; * suffering from malignant tumor diseases, congenital or acquired immune deficiency diseases, other systemic inflammatory response diseases; * Those who have recently been treated with high-risk immunosuppressive/cytotoxic drugs, such as rituximab, doxorubicin, or steroid hormones (20mg/d ponisone or higher) for more than 4 weeks; * Severe immunosuppression: adult neutrophils \<1 500/mm3, child neutrophils \<1 000/mm3; * Pregnancy or lactation; * There is a mental disability or active mental illness that prevents informed consent; * Conditions deemed unsuitable for study inclusion by other clinicians.